BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

775 related articles for article (PubMed ID: 12942553)

  • 21. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Kantarjian H; Talpaz M; O'Brien S; Giles F; Rios MB; White K; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Kornblau S; Cortes J
    Cancer; 2003 May; 97(9):2225-8. PubMed ID: 12712475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
    Cervantes F; Hernández-Boluda JC; Steegmann JL; Conde E; Alvarez-Larrán A; López-Jiménez J; Osorio S; Villalón L; Camós M; García-Conde J; Odriozola J
    Haematologica; 2003 Oct; 88(10):1117-22. PubMed ID: 14555307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
    Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Imatinib therapy for patients with chronic myelogenous leukemia].
    Usui N
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
    Marin D; Kaeda JS; Andreasson C; Saunders SM; Bua M; Olavarria E; Goldman JM; Apperley JF
    Cancer; 2005 May; 103(9):1850-5. PubMed ID: 15786422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
    Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
    Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
    Müller MC; Gattermann N; Lahaye T; Deininger MW; Berndt A; Fruehauf S; Neubauer A; Fischer T; Hossfeld DK; Schneller F; Krause SW; Nerl C; Sayer HG; Ottmann OG; Waller C; Aulitzky W; le Coutre P; Freund M; Merx K; Paschka P; König H; Kreil S; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Dec; 17(12):2392-400. PubMed ID: 14523462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    O'Brien SG; Deininger MW
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):26-30. PubMed ID: 12783372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Results of imatinib therapy in late-stage chronic myeloid leukemia after treatment with interferon-alpha].
    Molnár L; Nagy A; Dávid M; Szomor A; Méhes G; Kovács G; Losonczy H
    Orv Hetil; 2004 Apr; 145(17):901-7. PubMed ID: 15170967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quality of life on imatinib.
    Hahn EA; Glendenning GA
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):31-6. PubMed ID: 12783373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bone marrow morphologic features in patients treated with imatinib for Philadelphia chromosome positive chronic myeloid leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Shi HL; Lu Y; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2004 Mar; 25(3):158-62. PubMed ID: 15182585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome.
    Le Coutre P; Kreuzer KA; Na IK; Schwarz M; Lupberger J; Holdhoff M; Baskaynak G; Gschaidmeier H; Platzbecker U; Ehninger G; Prejzner W; Huhn D; Schmidt CA
    Am J Hematol; 2003 Aug; 73(4):249-55. PubMed ID: 12879428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; Smith TL; Cortes J; Giles FJ; Rios MB; Mallard S; Gajewski J; Murgo A; Cheson B; O'Brien S
    J Clin Oncol; 2000 Oct; 18(20):3513-21. PubMed ID: 11032593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
    Kolb EA; Pan Q; Ladanyi M; Steinherz PG
    Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.